Literature DB >> 34402262

Development of a nomogram for predicting survival of patients with ovarian serous cystadenocarcinoma after based on SEER database.

Xiaobin Chen1, Tingting Guo1.   

Abstract

To develop a survival time prediction model for patients with ovarian serous cystadenocarcinoma after surgery. A retrospective analysis of 5906 postoperative patients with ovarian serous cystadenocarcinoma in the surveillance, epidemiology, and end results (SEER) database from 2010 to 2015 was performed. The independent risk factors for long-term survival were analyzed with multivariate Cox proportional hazard regression model. The nomogram of 3-year and 5-year survival was developed by using R language. The receiver operator characteristic (ROC) curve and were used to test the discrimination of the model and the calibration diagram was used to evaluate the degree of calibration of the prediction model. The survival curves was conducted by the risk factors. Cox proportional hazard regression model showed that age, race, histological grade (poorly differentiated and undifferentiated), stage T (T2a, T2b, T2c, T3a, T3b and T3c), and stage M (M1) were independent factors for the prognosis of patients with ovarian serous cystadenocarcinoma after surgery. A nomogram was developed by the R language tool for predicting the 3-year and survival of patients through age, race, histological classification, stage T and stage M. The C-index was 0.688 and the areas under ROC curve of the nomogram for predicting 3-year and 5-year survival were 0.708 and 0.716, respectively. The results of the calibration indicated that the predicted values were consistent with the actual values in the prediction models. The survival time of patients with high-risk factors was shorter than that of patients with low-risk factors (<0.05). The developed nomogram in this study can be used to predict 3-year and 5-year survival of postoperative patients with ovarian serous cystadenocarcinoma, and it may be beneficial to guide clinical treatment.

Entities:  

Keywords:  Forecasting model; Nomogram; SEER database; Serous cystadenocarcinoma; Survival analysis

Mesh:

Year:  2021        PMID: 34402262      PMCID: PMC8710265          DOI: 10.3724/zdxbyxb-2021-0188

Source DB:  PubMed          Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban        ISSN: 1008-9292


  10 in total

1.  Evidence of benefit from centralised treatment of ovarian cancer: a nationwide population-based survival analysis in Finland.

Authors:  Salla Kumpulainen; Seija Grénman; Pentti Kyyrönen; Eero Pukkala; Risto Sankila
Journal:  Int J Cancer       Date:  2002-12-10       Impact factor: 7.396

2.  Revised FIGO staging for carcinoma of the cervix.

Authors:  Sergio Pecorelli; Lucia Zigliani; Franco Odicino
Journal:  Int J Gynaecol Obstet       Date:  2009-04-01       Impact factor: 3.561

3.  Associations between residual disease and survival in epithelial ovarian cancer by histologic type.

Authors:  Alexander Melamed; Beryl Manning-Geist; Amy J Bregar; Elisabeth J Diver; Annekathryn Goodman; Marcela G Del Carmen; John O Schorge; J Alejandro Rauh-Hain
Journal:  Gynecol Oncol       Date:  2017-08-16       Impact factor: 5.482

4.  Favorable clinical behavior in young ovarian carcinoma patients: a rationale for conservative surgery?

Authors:  J E Sardi; P Anchezar; A Bermudez
Journal:  Int J Gynecol Cancer       Date:  2005 Sep-Oct       Impact factor: 3.437

5.  Effect of delays in primary care referral on survival of women with epithelial ovarian cancer: retrospective audit.

Authors:  John M J Kirwan; Douglas G Tincello; Jonathan J O Herod; Olive Frost; Robert E Kingston
Journal:  BMJ       Date:  2002-01-19

6.  Reproductive and hormone-related risk factors for epithelial ovarian cancer by histologic pathways, invasiveness and histologic subtypes: Results from the EPIC cohort.

Authors:  Renée T Fortner; Jennifer Ose; Melissa A Merritt; Helena Schock; Anne Tjønneland; Louise Hansen; Kim Overvad; Laure Dossus; Françoise Clavel-Chapelon; Laura Baglietto; Heiner Boeing; Antonia Trichopoulou; Vassiliki Benetou; Pagona Lagiou; Claudia Agnoli; Amalia Mattiello; Giovanna Masala; Rosario Tumino; Carlotta Sacerdote; H B As Bueno-de-Mesquita; N Charlotte Onland-Moret; Petra H Peeters; Elisabete Weiderpass; Inger Torhild Gram; Eric J Duell; Nerea Larrañaga; Eva Ardanaz; María-José Sánchez; M-D Chirlaque; Jenny Brändstedt; Annika Idahl; Eva Lundin; Kay-Tee Khaw; Nick Wareham; Ruth C Travis; Sabina Rinaldi; Isabelle Romieu; Marc J Gunter; Elio Riboli; Rudolf Kaaks
Journal:  Int J Cancer       Date:  2015-02-26       Impact factor: 7.396

7.  Comparison of advanced stage mucinous epithelial ovarian cancer and serous epithelial ovarian cancer with regard to chemosensitivity and survival outcome: a matched case-control study.

Authors:  Emine Karabuk; M Faruk Kose; Deniz Hizli; Salih Taşkin; Burak Karadağ; Taner Turan; Nurettin Boran; Ahmet Ozfuttu; U Fırat Ortaç
Journal:  J Gynecol Oncol       Date:  2013-04-05       Impact factor: 4.401

8.  The Clinicopathologic Characteristics and 5-year Survival Rate of Epithelial Ovarian Cancer in Yazd, Iran.

Authors:  Mojgan Karimi-Zarchi; Seyed Mohammad Reza Mortazavizadeh; Nasrollah Bashardust; Neda Zakerian; Mahbube Zaidabadi; Pouria Yazdian-Anari; Soraya Teimoori
Journal:  Electron Physician       Date:  2015-10-19

Review 9.  Epigenetic Biomarkers in the Management of Ovarian Cancer: Current Prospectives.

Authors:  Alka Singh; Sameer Gupta; Manisha Sachan
Journal:  Front Cell Dev Biol       Date:  2019-09-19

10.  Comorbidity and survival of Danish ovarian cancer patients from 2000-2011: a population-based cohort study.

Authors:  Anne Fia Grann; Reimar Wernich Thomsen; Jacob Bonde Jacobsen; Mette Nørgaard; Jan Blaakær; Mette Søgaard
Journal:  Clin Epidemiol       Date:  2013-11-01       Impact factor: 4.790

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.